Eliford Ngaimisi

831 total citations
22 papers, 681 citations indexed

About

Eliford Ngaimisi is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Eliford Ngaimisi has authored 22 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 8 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Eliford Ngaimisi's work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and Drug Transport and Resistance Mechanisms (4 papers). Eliford Ngaimisi is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (8 papers) and Drug Transport and Resistance Mechanisms (4 papers). Eliford Ngaimisi collaborates with scholars based in Tanzania, Sweden and Germany. Eliford Ngaimisi's co-authors include Omary Minzi, Eleni Aklillu, Sabina Mugusi, Ferdinand Mugusi, Jürgen Burhenne, Mohammed Janabi, Philip Sasi, Walter E. Haefeli, Appolinary Kamuhabwa and Abiy Habtewold and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Eliford Ngaimisi

21 papers receiving 664 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eliford Ngaimisi Tanzania	16	333	171	160	153	143	22	681
Rosa F. Yeh United States	12	348 1.0×	88 0.5×	105 0.7×	166 1.1×	135 0.9×	25	682
Abiy Habtewold Ethiopia	15	361 1.1×	277 1.6×	116 0.7×	158 1.0×	172 1.2×	25	728
Philip Sasi Tanzania	15	250 0.8×	135 0.8×	105 0.7×	97 0.6×	118 0.8×	36	774
Sabina Mugusi Tanzania	13	364 1.1×	136 0.8×	119 0.7×	174 1.1×	150 1.0×	28	602
SH Khoo United Kingdom	15	614 1.8×	77 0.5×	166 1.0×	275 1.8×	200 1.4×	40	843
Natsuo Tachikawa Japan	16	533 1.6×	103 0.6×	66 0.4×	217 1.4×	284 2.0×	74	999
Deirdre Egan United Kingdom	15	730 2.2×	100 0.6×	223 1.4×	356 2.3×	199 1.4×	26	955
Edmund Ho United States	8	355 1.1×	107 0.6×	219 1.4×	117 0.8×	352 2.5×	9	918
Podjanee Jittamala Thailand	19	270 0.8×	119 0.7×	125 0.8×	53 0.3×	152 1.1×	38	1.1k
Eric C. M. Van Gorp Netherlands	13	388 1.2×	70 0.4×	81 0.5×	148 1.0×	69 0.5×	17	713

Countries citing papers authored by Eliford Ngaimisi

Since Specialization

Citations

This map shows the geographic impact of Eliford Ngaimisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliford Ngaimisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliford Ngaimisi more than expected).

Fields of papers citing papers by Eliford Ngaimisi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliford Ngaimisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliford Ngaimisi. The network helps show where Eliford Ngaimisi may publish in the future.

Co-authorship network of co-authors of Eliford Ngaimisi

This figure shows the co-authorship network connecting the top 25 collaborators of Eliford Ngaimisi. A scholar is included among the top collaborators of Eliford Ngaimisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliford Ngaimisi. Eliford Ngaimisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laffont, Céline M., Eliford Ngaimisi, Mathangi Gopalakrishnan, et al.. (2022). Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Frontiers in Pharmacology. 13. 1052113–1052113. 15 indexed citations

Minzi, Omary, Eliford Ngaimisi, Safari Kinung’hi, et al.. (2021). Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection. Pharmaceuticals. 14(5). 400–400. 10 indexed citations

Mugusi, Sabina, Abiy Habtewold, Eliford Ngaimisi, et al.. (2020). Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. Frontiers in Pharmacology. 11. 26–26. 16 indexed citations

Ngaimisi, Eliford, et al.. (2020). Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. Clinical Pharmacokinetics. 60(4). 527–540. 35 indexed citations

Mugusi, Sabina, Eliford Ngaimisi, Mohammed Janabi, et al.. (2018). Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. European Journal of Clinical Pharmacology. 74(11). 1405–1415. 8 indexed citations

Ngaimisi, Eliford, et al.. (2018). Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania. BMC Pharmacology and Toxicology. 19(1). 66–66. 1 indexed citations

Aklillu, Eleni, Abiy Habtewold, Eliford Ngaimisi, et al.. (2016). SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. OMICS A Journal of Integrative Biology. 20(9). 538–545. 24 indexed citations

Ngaimisi, Eliford, et al.. (2015). The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malaria Journal. 14(1). 179–179. 33 indexed citations

Minzi, Omary, et al.. (2015). CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. The Pharmacogenomics Journal. 16(1). 88–95. 42 indexed citations

10.

Ngaimisi, Eliford, Omary Minzi, Sabina Mugusi, et al.. (2014). Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. Journal of Antimicrobial Chemotherapy. 69(12). 3311–3319. 24 indexed citations

11.

Aklillu, Eleni, Linda Odenthal-Hesse, Abiy Habtewold, et al.. (2013). CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans. BMC Infectious Diseases. 13(1). 536–536. 15 indexed citations

12.

Machado, Lee R., Eliford Ngaimisi, Abiy Habtewold, et al.. (2013). Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa. PLoS ONE. 8(11). e78165–e78165. 14 indexed citations

13.

Ngaimisi, Eliford, Abiy Habtewold, Omary Minzi, et al.. (2013). Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. PLoS ONE. 8(7). e67946–e67946. 107 indexed citations

14.

Minzi, Omary, Seif Shekalaghe, Omar Juma, et al.. (2013). Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Malaria Journal. 12(1). 174–174. 14 indexed citations

15.

Mugusi, Sabina, Eliford Ngaimisi, Mohamed Janabi, et al.. (2012). Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. PLoS ONE. 7(7). e40180–e40180. 53 indexed citations

16.

Hardwick, Robert J., Wondwossen Amogne, Sabina Mugusi, et al.. (2012). -defensin Genomic Copy Number Is Associated With HIV Load and Immune Reconstitution in Sub-Saharan Africans. The Journal of Infectious Diseases. 206(7). 1012–1019. 32 indexed citations

17.

Minzi, Omary, et al.. (2012). Interlaboratory Development and Cross Validation of a Chromatographic Method for Determination of Lumefantrine in Human Plasma-A Proficient Capacity Assessment of Bioanalytical Laboratories in East Africa. Journal of Analytical & Bioanalytical Techniques. 3(2). 13 indexed citations

18.

Ngaimisi, Eliford, Sabina Mugusi, Omary Minzi, et al.. (2011). Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clinical Pharmacology & Therapeutics. 90(3). 406–413. 66 indexed citations

19.

Aklillu, Eleni, Sabina Mugusi, Eliford Ngaimisi, et al.. (2011). Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method. European Journal of Clinical Pharmacology. 67(11). 1139–1145. 33 indexed citations

20.

Ngaimisi, Eliford, Sabina Mugusi, Omary Minzi, et al.. (2010). Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients. Clinical Pharmacology & Therapeutics. 88(5). 676–684. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact